About B3B

This author has not yet filled in any details.
So far B3B has created 200 blog entries.

Spotlight: Q&A with Ian Chan, CEO & Founder, Abpro

About Abpro Abpro is an integrated life science company focused on industrial biochemistry. Through its DiversImmune™ platform, Abpro leverages synthetic biology and immunology to create novel biomolecules for use in research, diagnostics, animal health and therapeutics. Abpro’s platform has been validated by major pharmaceutical, biotechnology and academic labs around the world. What was your inspiration [...]

September 6th, 2016|

‘Bugs’ on the Subway: Monitoring Microbes in Transit

From press release of Harvard T.H. Chan School of Public Health: "The trillions of microbes that transfer from people to surfaces could provide an early warning system for the emergence of public health threats such as a flu outbreak or a rise in antibiotic resistance, according to a study from Harvard T.H. Chan School of [...]

June 30th, 2016|

Latest Startup From Harvard’s Springer Gets $51.5M

From press release: "Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin drugs, announced today that it has completed a $51.5 million Series A financing to advance multiple programs into the clinic. The round was co-led by SR One and Pfizer Venture Investments, joined by Omega Funds and AbbVie Ventures. They join [...]

June 30th, 2016|

Medtronic to Acquire HeartWare in $1.1B Deal

Intro of HeartWare press release: "Medtronic plc (NYSE: MDT), the global leader in medical technology, and HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies for the treatment of advanced heart failure, today announced that the companies have entered into a definitive merger agreement under which Medtronic will acquire HeartWare in [...]

June 27th, 2016|

GE Healthcare Bets Big on Boston

Opens Life Sciences North American HQ to Accelerate Precision Medicine Intro of GE press release: "GE Healthcare’s Life Sciences business, a global provider of technologies and expertise to the biopharmaceutical and life sciences industries, today opened its new 210,000 square-foot North American headquarters in Marlborough, Massachusetts. At full capacity in 2017, it will employ more than [...]

June 24th, 2016|

Rapid Detection of Zika & Future Pandemics

From Wyss Institute: "The rapid emergence of the Zika virus on the world stage calls for a detection system that is just as quick. In this episode of Disruptive, Wyss Core Faculty member and MIT professor Jim Collins and University of Toronto Assistant Professor Keith Pardee discuss how they developed a low cost, paper-based diagnostic [...]

June 23rd, 2016|

Boston Business Journal: Zika Virus Test OK’d

(NOTE: You may have to disable ad-blocking to view video) From NECN: "A test developed in Massachusetts to detect the presence of the zika virus in blood has gotten FDA approval. Boston Business Journal's Don Seiffert joins us with more"

June 22nd, 2016|

Life In The Trenches Of A Biotech LLC

Jeb Keiper, CBO of Nimbus Therapeutics LLC, has written a great blogpost (as part of the "From The Trenches" feature of LifeSciVC) about corporate financing, program-focused subsidiaries, the differences between "inc." and "llc", and much more. The intro: "Unsurprisingly, I had not given that much thought to the parent entity of my new employer when [...]

June 21st, 2016|

Bill Gates Talks Biotech

Coverage from Bill Gates speaking at the ASM Microbe 2016 conference at the Boston Convention & Exhibition Center: Excerpt from his special Q&A with STAT: "We heard that you met with some scientists here to have some one-on-ones. We’re curious about your personal interest in science. It’s a very fun part of my job. Last week, [...]

June 17th, 2016|

How to Pay for Cutting-Edge Drugs?

In the feature "Promising gene therapies pose million-dollar conundrum," Erika Check Hayden/Nature details how stakeholders in various segments of the life sciences and healthcare are trying to wrangle through the financial/pricing knots of gene therapies. The intro: "Drugs that act by modifying a patient’s genes are close to approval in the United States, and one is already available in [...]

June 15th, 2016|